MA52548A - Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches - Google Patents

Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches

Info

Publication number
MA52548A
MA52548A MA052548A MA52548A MA52548A MA 52548 A MA52548 A MA 52548A MA 052548 A MA052548 A MA 052548A MA 52548 A MA52548 A MA 52548A MA 52548 A MA52548 A MA 52548A
Authority
MA
Morocco
Prior art keywords
oytocin
diagrams
embryo implantation
dosage regimes
prevent mis
Prior art date
Application number
MA052548A
Other languages
English (en)
Inventor
Jean-Pierre Gotteland
Ernest Loumaye
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of MA52548A publication Critical patent/MA52548A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
MA052548A 2016-07-21 2017-07-20 Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches MA52548A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662365147P 2016-07-21 2016-07-21
US201762527721P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
MA52548A true MA52548A (fr) 2021-05-26

Family

ID=59501409

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052548A MA52548A (fr) 2016-07-21 2017-07-20 Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches

Country Status (15)

Country Link
US (1) US20190247361A1 (fr)
EP (2) EP3487493B1 (fr)
JP (3) JP7036791B2 (fr)
KR (3) KR20250079242A (fr)
CN (3) CN109689048B (fr)
AU (3) AU2017300026B2 (fr)
BR (1) BR112019001047A2 (fr)
CA (1) CA3031252A1 (fr)
ES (1) ES2898778T3 (fr)
IL (1) IL264243B2 (fr)
MA (1) MA52548A (fr)
MX (1) MX389041B (fr)
SG (1) SG11201900461UA (fr)
UA (1) UA127283C2 (fr)
WO (1) WO2018015497A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019230919A1 (fr) 2018-05-31 2019-12-05 小野薬品工業株式会社 Biomarqueur pour évaluer l'efficacité d'un inhibiteur de point de contrôle immunitaire
JP7584201B2 (ja) * 2019-09-03 2024-11-15 オブセヴァ エス.エー. 薬学的組成物
US20230102503A1 (en) * 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
WO2026018221A1 (fr) * 2024-07-18 2026-01-22 ReproNovo SA Compositions cristallines pour améliorer l'implantation d'embryons et leurs procédés d'utilisation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780725A (en) 1971-03-04 1973-12-25 Smith Kline Instr Fetal heartbeat monitoring system with plural transducers in one plane and at different angles thereto
NL7511109A (nl) 1974-11-11 1976-05-13 Carter Wallace Werkwijze en middel voor het vaststellen van hor- moon in waterig milieu, in het bijzonder voor zwangerschapsonderzoek.
IL56342A (en) 1978-12-29 1982-05-31 Zer Tamar Method and means for determining human chorionic gonadotropin in urine
SE430885B (sv) 1980-03-24 1983-12-19 Ferring Ab Oxytocin-derivat
US4437467A (en) 1981-12-11 1984-03-20 American Home Products Corporation Apparatus for monitoring fetal heartbeat and the like
DE10075020I2 (de) 1982-12-21 2003-01-09 Ferring Ab Vasotocinderivate
US4720455A (en) 1985-09-06 1988-01-19 Pitman-Moore, Inc. Progesterone assay method for mammals and monoclonal antibody therefor
WO1991003935A1 (fr) 1989-09-22 1991-04-04 Tsi-Mason Research Institute Procede et compositions de cryoconservation en une etape d'embryons
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
AU772190B2 (en) 1998-08-11 2004-04-08 University Of Hawaii Mammalian transgenesis by intracytoplasmic sperm injection
CN100536912C (zh) 2001-09-12 2009-09-09 雪兰诺实验室有限公司 人绒毛膜促性腺激素在控制性超排卵中的应用
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
EP1480998B1 (fr) 2002-02-27 2006-11-22 Ferring BV Intermediaires et procedes destines a fabriquer des analogues d'oxytocine heptapeptide
US7815912B2 (en) 2002-06-07 2010-10-19 Ares Trading, S.A. Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
DK1646389T3 (da) 2003-07-07 2009-01-05 Neurocrine Biosciences Inc Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
WO2006121362A2 (fr) * 2005-05-10 2006-11-16 Ferring International Center Sa. Utilisation d'antagonistes de l'oxytocine et/ou de la vasopressine
WO2008051620A2 (fr) 2006-10-24 2008-05-02 University Of Hawaii Methodes et compositions de transgenese par injection intracytoplasmique de spermatozoides
US7989217B2 (en) 2007-03-29 2011-08-02 Ameritek Usa, Inc. Method for determining hCG levels in fluid samples
JP2011528907A (ja) 2008-07-23 2011-12-01 マリポサ バイオテクノロジー, インコーポレイテッド 卵母細胞、胚または胚盤胞の凍結保存のための自動化システム
US9201077B2 (en) * 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
WO2011051814A1 (fr) 2009-10-30 2011-05-05 Glaxo Group Limited Nouvelles formes cristallines de (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - diméthyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoéthyl] -6- [(1s) - 1 -méthylpropyl] -2,5- pipérazinedione
WO2013158658A1 (fr) 2012-04-16 2013-10-24 Cornell University Système de fertilisation assistée par injection intracytoplasmique automatisée de sperme
US8937139B2 (en) 2012-10-25 2015-01-20 Chevron Phillips Chemical Company Lp Catalyst compositions and methods of making and using same
US20160278688A1 (en) * 2012-11-26 2016-09-29 Ferring B.V. Method and System for Diagnosing Uterine Contraction Levels Using Image Analysis
EP2845850A1 (fr) * 2013-09-10 2015-03-11 ObsEva S.A. Dérivés de pyrrolidine comme antagonistes des récepteurs V1a de vasopressine/oxytocine
EP2886107A1 (fr) 2013-12-17 2015-06-24 ObsEva S.A. Formules orales de dérivés de pyrrolydine
KR102470283B1 (ko) * 2014-07-02 2022-11-23 옵스에파 에스에이 결정질 (3z,5s)-5-(하이드록시메틸)-1-[(2'-메틸-1,1'-바이페닐-4-일)카르보닐]피롤리딘-3-온 o-메틸옥심
PL3037101T3 (pl) 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu
US20180282367A1 (en) 2015-10-06 2018-10-04 Ferring B.V. New methods for making barusiban and its intermediates

Also Published As

Publication number Publication date
JP2022078194A (ja) 2022-05-24
CN115569132A (zh) 2023-01-06
US20190247361A1 (en) 2019-08-15
WO2018015497A2 (fr) 2018-01-25
JP7036791B2 (ja) 2022-03-15
JP2024095703A (ja) 2024-07-10
CN115590849A (zh) 2023-01-13
EP3487493A2 (fr) 2019-05-29
CA3031252A1 (fr) 2018-01-25
KR20250079242A (ko) 2025-06-04
WO2018015497A3 (fr) 2018-03-01
IL264243B2 (en) 2023-02-01
MX2019000498A (es) 2019-09-16
BR112019001047A2 (pt) 2019-04-30
AU2017300026B2 (en) 2023-07-13
CN109689048B (zh) 2022-10-28
EP3487493B1 (fr) 2021-09-01
MX389041B (es) 2025-03-20
SG11201900461UA (en) 2019-02-27
ES2898778T3 (es) 2022-03-08
JP2019523251A (ja) 2019-08-22
KR20230165386A (ko) 2023-12-05
AU2017300026A1 (en) 2019-02-28
UA127283C2 (uk) 2023-07-12
AU2023237170A1 (en) 2023-10-19
KR20190039725A (ko) 2019-04-15
IL264243A (en) 2019-02-28
AU2026201746A1 (en) 2026-03-26
IL264243B (en) 2022-10-01
EP4056178A1 (fr) 2022-09-14
CN109689048A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
FR25C1045I1 (fr) Composition ophthalmique contenant un antagoniste de recepteurs muscariniques et d'eau deuterisée
PL3889145T3 (pl) 8-cyjano-5-piperydyno-chinoliny jako antagoniści TLR7/8 oraz ich zastosowanie w leczeniu zaburzeń immunologicznych
DK3381451T3 (da) Farmaceutisk sammensætning brugt til at reducere lokaliseret fedt samt brug af den farmaceutiske sammensætning
IL247459B (en) Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof
EP3414405A4 (fr) Bouchons et corps d'ancrage de béton
EP3019491A4 (fr) Inhibiteurs de kinase pour le traitement d'une maladie
EP3420002A4 (fr) Antagonistes d'actrii pour leur utilisation dans l'accroissement de l'activité immunitaire
SI3122775T1 (sl) Monoklonska protitelesa proti rastnemu in diferenciacijskemu faktorju 15 (GDF-15) in njihove uporabe za zdravljenje kahesije pri raku in raka
HRP20251694T1 (hr) Optimizirano doziranje diaminofenotiazina u populacijama
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
EP3435981A4 (fr) Compositions et procédés pour stimuler l'immunité innée
EP3005907A4 (fr) Matelas pour réunir et répartir de façon uniforme la gravité d'un corps humain
MA52548A (fr) Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches
HUE057257T2 (hu) Folyékony készítmény gyomor- és nyelõcsõ reflux kezelésében történõ alkalmazásra
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
EP3204028A4 (fr) Composition synergique pour l'arthrose
EP3342784A4 (fr) Anticorps entièrement humain inhibant en particulier la connexine 26
EP3741376A4 (fr) Probiotiques pour inhiber et prévenir l'évolution de maladies rénales et compositions pour inhiber et prévenir l'évolution de maladies rénales les comprenant
EP3313380A4 (fr) Composition pour l'administration d'agents actifs à un animal
HRP20182033T1 (hr) Uređaj u obliku kompleta za miješanje i injiciranje koštanog cementa
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
SI3124048T1 (sl) Sestavek za peroralno uporabo pri zdravljenju gastroezofagealne refluksne bolezni ali neugodja
EP3319980A4 (fr) Formulations permettant d'améliorer l'efficacité des médicaments hydrophobes
EP3700459C0 (fr) Ensemble d'implantation dentaire endo-osseux